LB Pharmaceuticals Inc Appoints Chief Medical Officer Susan G. Kozauer

What Happened LB Pharmaceuticals Inc. announced on Sept. 15, 2026 (effective Sept. 14, 2026) that Susan G. Kozauer, M.D. (age 54) has been appointed Chief Medical Officer. Dr. Kozauer joins from Centessa Pharmaceuticals, where she was Senior VP, Head of Clinical Development (Aug 2025–Sept 2026), and previously served as VP, Clinical Development at Intra-Cellular Therapies (Nov 2017–Aug 2025). Her academic credentials include a BA from Cornell, an MD from George Washington University, and a psychiatry residency at Georgetown University Medical Center.

Key Details

• Annual base salary: $515,000; target annual discretionary bonus: 40% of base salary.
• Sign-on bonus: $150,000 payable within 30 days of start; 50% of the sign-on bonus vests on each of the first and second anniversaries and unvested portions must be repaid if employment ends before the second anniversary.
• Equity: option to purchase 200,000 common shares granted as an inducement (outside but subject to the 2025 Equity Incentive Plan); vests over four years (25% at 1 year, then monthly thereafter).
• Severance: if terminated without cause or resigns for good reason (not in connection with a change of control) — nine months of base salary continuation plus up to nine months COBRA premiums; enhanced severance for termination within change-of-control window (one year base salary + 150% of target bonus, 12 months COBRA reimbursement, and full acceleration of unvested equity).
• Other: employment is at-will; customary confidentiality and 12‑month non-solicit; Company will enter its standard indemnification agreement. No related-party transactions or family ties disclosed.

Why It Matters This is a material executive hire for LB Pharmaceuticals’ clinical leadership and could influence the company’s clinical strategy and development timelines. The compensation package includes meaningful up-front pay, a sizeable equity inducement (200,000‑share option) and typical severance protections, including enhanced benefits on a change of control — all items investors watch for potential dilution, cash outflows, and alignment of management incentives with shareholders. The company filed a press release and will include the full employment agreement as an exhibit to its next Form 10-Q.